Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine

The association of antipsychotics is a widespread therapeutic resource in clinical practice. The purpose of the present work was to evaluate the effi cacy and safety of amisulpride augmentation in patients responding at least partially to olanzapine. Methods: In this observational 3-months open-label investigation, we evaluated the eff ectiveness of the addition of amisulpride to 49 subjects, after having scored at least 25 on the brief psychiatric rating scale (BPRS) following olanzapine monotherapy for 6 weeks. Patients were assessed at baseline, 1 and 3 months using the BPRS, the clinical global impression severity of illness (CGI-S) scale and the Udvalg for Kliniske Undersogelser side eff ect rating scale (UKU)